Search

(D6) Drug Pipeline: Traditional Pharmaceuticals (Brands and Generics)
Policy Outlook 2025: The Trump Administration and the 119th Congress
(L1) Legislative Impacts on Site of Service: What is the Big Deal?
(R1) Unlocking the Value of Real-World Evidence (RWE): Insights for Payers and Manufacturers
(W1) The Regulatory Landscape of AI in Managed Care Pharmacy: Compliance, Ethics, and Future Trends
(D1) Charting a Better Path in Managing Multiple Myeloma: Overcoming Challenges and Driving Solutions
(W2) Chimeric Antigen Receptor T-Cell (CAR-T) Therapies: Perspectives and Challenges in Managed Care
(SP1) Unlocking the Basics of Value-Based Contracting: A Hands-On Introduction
(M2) Employer Perspectives on High-Impact Drugs
(L2) Inflation Reduction Act Ripple Effects: Considerations for Patient Access and 340B
(D2) Advancing Equitable Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) Management Strategies in Managed Care
(M1) Patient Engagement in Managed Care Pharmacy: Putting Policy into Practice
(D5) Mind Over Migraines: Disease Burden, Innovative Therapies, and Managed Care Trends in Treating Migraines
(R5) Accelerated Approvals, Where Are We Now? A Follow Up on The Advantages and Pitfalls
(K2) GLP-1’s for Everything! The gift that keeps on giving… A review of the body of evidence and implications for managed care
(K3) Specialty Pharmaceuticals in Development
(L6) Understanding 340B Stakeholder Perspectives, Litigation Trends, and Reform Prospects
[eLD 1] Navigating the Evolving Landscape of Cell and Gene Therapies: Key Insights for Managed Care Professionals
[eLD 2] Overcoming Barriers and Understanding the Patient and Payer Journey with Sickle Cell Therapy
Charting a Better Path in Managing Multiple Myeloma: Overcoming Challenges and Driving Solutions

Pages